<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol Rep</journal-id><journal-id journal-id-type="iso-abbrev">Curr Oncol Rep</journal-id><journal-title-group><journal-title>Current Oncology Reports</journal-title></journal-title-group><issn pub-type="ppub">1523-3790</issn><issn pub-type="epub">1534-6269</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39836349</article-id><article-id pub-id-type="pmc">PMC11861112</article-id>
<article-id pub-id-type="publisher-id">1634</article-id><article-id pub-id-type="doi">10.1007/s11912-024-01634-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Cardiotoxic Effects Following CAR-T Cell Therapy: A Literature Review</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Joseph</surname><given-names>Tony</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Sanchez</surname><given-names>Jimmy</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Abbasi</surname><given-names>Ahmed</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lili</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Sica</surname><given-names>R. Alejandro</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Duong</surname><given-names>Tim Q.</given-names></name><address><email>tim.duong@einsteinmed.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cf8a891</institution-id><institution-id institution-id-type="GRID">grid.251993.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 1997</institution-id><institution>Department of Radiology, Albert Einstein College of Medicine and the Montefiore Medical Center, </institution></institution-wrap>111 East 210Th Street, Bronx, NY 10461 USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/019k4jq75</institution-id><institution-id institution-id-type="GRID">grid.183006.c</institution-id><institution-id institution-id-type="ISNI">0000 0001 0671 7844</institution-id><institution>Department of Chemistry, </institution><institution>CUNY Brooklyn College, </institution></institution-wrap>2900 Bedford Ave, Brooklyn, NY 11210 USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cf8a891</institution-id><institution-id institution-id-type="GRID">grid.251993.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 1997</institution-id><institution>Department of Oncology, Albert Einstein College of Medicine and the Montefiore Medical Center, </institution></institution-wrap>111 East 210Th Street, Bronx, NY 10461 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05cf8a891</institution-id><institution-id institution-id-type="GRID">grid.251993.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2179 1997</institution-id><institution>Department of Medicine, Cardiology Division, Albert Einstein College of Medicine and the Montefiore Medical Center, </institution></institution-wrap>111 East 210Th Street, Bronx, NY 10461 USA </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>27</volume><issue>2</issue><fpage>135</fpage><lpage>147</lpage><history><date date-type="accepted"><day>30</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose of Review</title><p id="Par1">This paper reviewed the current literature on incidence, clinical manifestations, and risk factors of Chimeric Antigen Receptor T-cell (CAR-T) cardiotoxicity.</p></sec><sec><title>Recent Findings</title><p id="Par2">CAR-T therapy has emerged as a groundbreaking treatment for hematological malignancies since FDA approval in 2017. CAR-T therapy is however associated with a few side effects, among which cardiotoxicity is of significant concern. There were only a few studies on CAR-T cardiotoxicity published to date with limited sample sizes, and their findings were heterogeneous. It was difficult to reach generalizable conclusions.</p></sec><sec><title>Summary</title><p id="Par3">CAR-T therapy was associated with significant risks for acute and subacute cardiotoxicity, as measured by echocardiograms, EKG, and blood biomarkers. Patients with cytokine release syndrome (CRS) grade 2 or higher were more likely to exhibit cardiotoxicity. The most prevalent cardiac events included hypotension-requiring inotropic or vasopressor support, tachycardia, heart failure/decompensation, atrial fibrillation, new or worsening cardiomyopathy, arrhythmia, myocarditis, cardiac arrest, and cardiovascular death. The most prevalent echocardiographic changes were systolic dysfunction and diastolic dysfunction, and abnormal echocardiogram findings. There were differences in findings between adult and pediatric patients. The long-term effects beyond a year post treatment remain largely unknown and long-term follow-up studies are warranted.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s11912-024-01634-2.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cardiotoxicity</kwd><kwd>Cytokine release syndrome (CRS)</kwd><kwd>Echocardiogram</kwd><kwd>ECG</kwd><kwd>EKG</kwd><kwd>Blood biomarkers</kwd><kwd>Hypotension</kwd><kwd>Troponin (TNT)</kwd><kwd>Diastolic dysfunction</kwd><kwd>Atrial arrhythmia</kwd><kwd>Cardiomyopathy</kwd><kwd>Cancer immunotherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par4">Chimeric Antigen Receptor T-cell (CAR-T) therapy represents a major advancement in cancer treatment, particularly for patients with refractory or relapsed B-cell malignancies. CAR-T cells are engineered first, collecting T-cells from the patient through leukapheresis [<xref ref-type="bibr" rid="CR1">1</xref>]. Next, the T-cells are genetically modified to express chimeric antigen receptors (CARs) that recognize specific antigens on cancer cells. Then, the modified T-cells are expanded in culture to sufficient numbers. The CAR-T cells are then reinfused into the patient, where they seek out and destroy cancer cells expressing the target antigen. CAR-T therapy has achieved remarkable clinical success [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. However, this therapy is not without risks, and one of the potentially serious adverse effects is cardiotoxicity. Understanding the incidence, types of cardiotoxicities, risk factors, underlying mechanisms and clinical management of CAR-T-associated cardiotoxicity is crucial for optimizing patient outcomes.</p><p id="Par5">Cardiotoxicity associated with CAR-T therapy can manifest in several forms, including acute coronary syndrome, heart failure, arrhythmias, and pericarditis/myocarditis [<xref ref-type="bibr" rid="CR4">4</xref>]. The incidence of cardiotoxicity varies across studies [<xref ref-type="bibr" rid="CR5">5</xref>]. Cardiotoxic events can occur early, within days to weeks after infusion, or later, highlighting the need for long-term monitoring [<xref ref-type="bibr" rid="CR6">6</xref>]. Several mechanisms have been proposed for CAR-T-induced cardiotoxicity. One primary mechanism is cytokine release syndrome (CRS), a systemic inflammatory response characterized by elevated levels of cytokines such as interleukin (IL)&#x02212;6, which can lead to depression of myocardial function and increased&#x000a0;permeability of microvasculature&#x000a0;[<xref ref-type="bibr" rid="CR7">7</xref>]. CRS is a clinical diagnosis and usually presents with varying degrees of fever, tachycardia, hypotension, hypoxia, nausea, vomiting, etc. CRS grades range from 1 to 4, as defined by the American Society for Transplantation and Cellular Therapy (Supplemental Table <xref rid="MOESM1" ref-type="media">1</xref>) [<xref ref-type="bibr" rid="CR8">8</xref>]. Direct cardiotoxic effects may occur through the interaction of CAR-T cells with cardiac tissue expressing low levels of target antigens [<xref ref-type="bibr" rid="CR9">9</xref>]. Off-target effects can result from unintended targeting of antigens shared between malignant and healthy cardiac cells [<xref ref-type="bibr" rid="CR10">10</xref>]. The only risk factor that was consistently noted across literature for developing cardiotoxicity in CAR-T therapy was the severity of CRS [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR11">11</xref>]. Serial cardiac monitoring is important, and typical measurements include echocardiogram (ECG), echocardiogram (echo), or cardiac blood biomarkers (e.g., troponin and brain natriuretic peptide (BNP)) to assess cardiac function. The current literature on cardiotoxicity remains sparse and studies typically consist of small sample sizes. The incidence of CAR-T cardiotoxicity, its clinical manifestations and the risk factors for developing CAR-T cardiotoxicity in the literature are highly variable and it is difficult to generalize.</p><p id="Par6">The goal of this paper was to review the literature and characterize the incidence, clinical manifestations, and risk factors associated with CAR-T cardiotoxicity.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Search Strategy and Eligibility Criteria</title><p id="Par7">No ethics committee approval was required for this systematic review. PRIMSA guidelines were used to conduct our systematic review. A literature search was performed from 2017 to June 1st, 2024 using the following search terms that were found in either the title or abstract of the paper: &#x0201c;Chimeric Antigen Receptor T Cell therapy&#x0201d;, &#x0201c;CAR T&#x0201d;, &#x0201c;CAR-T&#x0201d;, or &#x0201c;Chimeric antigen receptors redirect T cell&#x0201d;, and &#x0201c;cardiotoxicity&#x0201d;, &#x0201c;cardiovascular&#x0201d;, cardiac&#x0201d; or &#x0201c;MACE&#x0201d;. Such search terms were used to encompass all phrases of CAR-T therapy. The PubMed database was used to conduct the literature search. We noted that papers relevant to our study were not identified through the PubMed search but was later identified and assessed. Articles that were not relating to CAR-T therapy or its adverse events were removed. Only papers that were written in English were included in this study. The initial search and screening were performed by TJ and independently verified by JS. Oncological therapies other than CAR-T were not reviewed in this study.</p></sec></sec><sec id="Sec4"><title>Results and Discussion</title><p id="Par8">The PubMed search yielded 156 articles, of which 32 were review or perspective articles, 2 were published before 2017, 81 did not report adverse effects of CAR-T therapy, and 30 did not investigate cardiotoxic effects of CAR-T therapy (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Eleven articles were found in the PubMed search after exclusion. In addition, 2 articles were found outside of the PubMed search that discussed cardiotoxic effects of CAR-T therapy.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>PRIMSA Selection Flowchart</p></caption><graphic xlink:href="11912_2024_1634_Fig1_HTML" id="MO1"/></fig></p><p id="Par9">A total of 13 articles were included in our study. In this review, we described and discussed individual papers in alphabetic orders, followed by summary findings, and future perspectives.</p><sec id="Sec5"><title>Summary of Individual Papers</title><p id="Par10">Alvi et al. [<xref ref-type="bibr" rid="CR12">12</xref>] performed a retrospective cohort study composed of 137 patients, with a median age of 62 (IQR: 54&#x02013;70). 54 patients developed CRS grade 2 or higher, while 6 patients developed CRS grade 3 or higher. 17 adverse cardiac effects were noted, which included 6 cardiovascular deaths, 6 decompensated HF, and 5 new-onset arrhythmias. All 17 patients who experienced adverse cardiac events had CRS grade 2 or higher. All 6 patients who experienced cardiovascular death has BNP levels greater than 3,000&#x000a0;pg/mL. Of the 29 patients who had pre and post echocardiographic data, 8 patients experienced a reduction in left ventricular ejection fraction (LVEF). Additionally, 53 patients also have pre and post troponin levels taken, of which 29 had an increase in troponin levels after CAR-T infusion. It was noted that patients with increased troponin levels were older (64&#x02009;&#x000b1;&#x02009;9.5&#x000a0;years) in comparison to patients who did not experience elevated troponin levels (58&#x02009;&#x000b1;&#x02009;8.7&#x000a0;years) (p&#x02009;=&#x02009;0.02). Additionally, certain cardiac risk factors were higher in the elevated troponin cohort, such as diabetes, hypertension, hyperlipidemia, atrial fibrillation/flutter, and CAD, although insignificant (p&#x02009;&#x0003e;&#x02009;0.05). 16 adverse cardiac events occurred in the elevated troponin cohort, compared to one adverse cardiac event in patients who did not experience elevated troponin. Lastly, CRS grade 2 or higher was associated with elevated troponin levels (p&#x02009;&#x0003c;&#x02009;0.001) as 83% of the elevated troponin cohort experienced CRS grade 2 or higher, compared to only 33% in the non-elevated troponin cohort.</p><p id="Par11">Brammer et al. [<xref ref-type="bibr" rid="CR13">13</xref>] performed a retrospective study composed of 90 patients, with an average age of 61&#x02009;&#x000b1;&#x02009;10.9&#x000a0;years. Eighty patients developed CRS, of which 44 patients developed CRS grade 2 or higher. Common symptoms of patients with CRS included hypotension (79 patients) and fever. 17 adverse cardiac events were reported, including 11 patients with arrhythmia, 2 patients with myocarditis, 1 patient with heart failure, and no cardiovascular deaths.</p><p id="Par12">Burstein et al. [<xref ref-type="bibr" rid="CR14">14</xref>] performed a retrospective study composed of 98 patients, with a median age of 10 (Range: 2&#x02013;27). 24 patients experienced hypotension-requiring inotropic support. In this cohort, no cardiovascular deaths were observed, how one patient suffered from a cardiac arrest that occurred 2&#x000a0;months after CAR-T infusion. This study noted how of the 24 patients that experienced hypotension-requiring inotropic support, 10 patients presented with abnormal echocardiograms, all of which revealed systolic dysfunction. 13 patients had serum cardiac biomarker data available, of which 12 patients presented with abnormal BNP levels. Evaluation of risk factors for patients with hypotension-requiring inotropic support revealed that no significant differences in age, sex, and race were found between patient cohorts who did or did not experience hypotension-requiring inotropic support. However, patients with baseline characteristics of reduced LVEF (p&#x02009;=&#x02009;0.019) or diastolic dysfunction (p&#x02009;=&#x02009;0.021) were observed to have increased rates of hypotension-requiring inotropic support.</p><p id="Par13">Fitzgerald et al. [<xref ref-type="bibr" rid="CR15">15</xref>] performed a retrospective cohort study composed of 39 patients, with a median age of 11 (Range: 5&#x02013;22) In total 36 patients developed CRS, with 34 patients developing CRS grade 2 or higher. Common symptoms of CRS included prolonged high fevers, tachycardia, and myalgias. In total, 14 patients had an adverse cardiac event; 13 patients had had profound fluid-refractory vasodilatory shock and 1 patient had cardiomyopathy. This singular patient was also observed to have decreased LVEF values and systolic dysfunction. Organ dysfunction was also noted in 25 patients, which was most commonly hepatic dysfunction. In addition, respiratory failures were also studied. Of the 39 cohort, 8 patients had respiratory failure; of which, 5 patients were later diagnosed with pediatric acute respiratory distress syndrome (PARDS).</p><p id="Par14">Ganatra et al. [<xref ref-type="bibr" rid="CR16">16</xref>] performed a retrospective cohort study composed of 187 patients, with a median age of 63 (Range: 19&#x02013;80). 12 patients developed new or worsening cardiomyopathy and experienced a decrease in median LVEF from 58 to 37% after CAR-T infusion. Of these 12 patients, 6 experienced heart failure. 13 patients developed new or worsening arrhythmia, and 86 patients developed CRS grade 2 or higher. 4 patients died in the hospital.</p><p id="Par15">Korell et al. [<xref ref-type="bibr" rid="CR17">17</xref>] performed a prospective cohort study with 137 patients, with a median age of 60 (Range: 20&#x02013;83). 25 patients experienced hypotension, 5 patients developed new atrial fibrillation. 75 patients developed CRS, of which 5 patients developed CRS grade 3 or higher. 17 patients developed cardiac decompensation. In terms of echocardiographic findings, 8 patients had abnormal echocardiogram changes, 5 of which were related to atrial fibrillation and 3 of which were unspecific. Additionally, 4 patients had a drop in LVEF measures after CAR-T infusion, of which one patient experienced a decrease of LVEF greater than 10%, while three patients experienced a decrease of LVEF below 50%. Both CRS grade 3 (p&#x02009;&#x0003c;&#x02009;0.001) or higher and ICANS (p&#x02009;=&#x02009;0.012) were identified as a risk factor for survival.</p><p id="Par16">Lee et al. [<xref ref-type="bibr" rid="CR18">18</xref>] performed an observational study on 90 patients, with a median age of 68. A total of 11 adverse cardiac events were reported, 10 patients developed atrial fibrillation, while 1 patient developed cardiomyopathy, which was later reported as acute myocarditis evidenced on cardiac MRI. This patient also presented with abnormal echocardiogram findings and reduced LVEF, which was defined as either a decrease of LVEF greater than 10% or a decrease of LVEF below 50%. Cardiac comorbidities were not found to be significantly different between cardiac events and non-cardiac events groups. Patients in the cardiac event group were statistically older, had higher baseline creatinine, and a larger indexed left atrium volume. 31 patients developed CRS grade 2 or above, of which 6 belonged to the cardiac events group and 25 belonged to the non-cardiac events group. Survival outcomes between the cardiac events group and no-cardiac events group was not significantly different. Of the 88 patients with cardiac biomarker data, there was no difference in Day 5 troponin levels between the cardiac events group and non-cardiac events group. However, all patients in the cardiac events group had BNP levels (125.0&#x000a0;ng/dL) larger (p&#x02009;=&#x02009;0.019) than the no-cardiac events group (63.0&#x000a0;ng/dL). In this study, abnormal troponin levels were defined as greater than 0.03&#x000a0;ng/mL, and abnormal BNP levels were defined as greater than 100&#x000a0;pg/mL.</p><p id="Par17">Lefebvre et al. (2020) [<xref ref-type="bibr" rid="CR19">19</xref>] performed a retrospective study composed of 145 patients, with a median age of 60 (IQR: 50&#x02013;66). 31 patients experienced adverse cardiac events. 2 patients died due to cardiac causes. 21 patients experienced heart failure and 11 patients experienced atrial fibrillation. 2 events of other arrhythmias (supraventricular tachycardia and non-sustained ventricular tachycardia) and 2 events of ACS was noted as well. 104 patients experienced CRS grade 2 or higher. It was also noted that CRS grade 3 and 4 were independently associated with adverse cardiac events. Lastly, it was noted that 22 patients had grade 1 diastolic dysfunction, 1 patient had grade 2 diastolic dysfunction, 3 patients had grade 2 diastolic dysfunction, and 21 patients had indeterminate diastolic function.</p><p id="Par18">Lefebvre et al. (2023) [<xref ref-type="bibr" rid="CR20">20</xref>] performed a prospective observational study composed of 44 patients, with an average age of 58 (&#x000b1;&#x02009;11). 11 patients experienced CRS grade 2 or higher. No significant differences in clinical or echocardiographic baseline characteristics were noted in patients who did or did not develop CRS. No significant differences in LVEF were noted as well. In the 23 patients who developed CRS of any grade, 14 patients had elevated BNP levels compared to their baseline characteristics (362&#x000a0;pg/mL vs 63&#x000a0;pg/mL). One patient developed HF and one patient developed atrial fibrillation.</p><p id="Par19">Maude et al. [<xref ref-type="bibr" rid="CR3">3</xref>] performed a single-center phase 1&#x02013;2a study composed of 75 patients, with a median age of 11 (Range: 3&#x02013;23). It was noted that 71 patients had a minimum of one adverse event believed to be due to CAR-T infusion. The most common symptoms of patients after infusion included CRS, pyrexia, decreased appetite, febrile neutropenia, and headache. 35 patients developed CRS grade 3 or higher. Additionally, this study recorded 30 patients experiencing neurologic events, which included encephalopathy, confusional state, delirium, tremor, agitation, somnolence, and seizure. Most of these neurologic events occurred following CRS. Lastly, 13 patients developed hypotension after CAR-T infusion.</p><p id="Par20">Neelapu et al. [<xref ref-type="bibr" rid="CR21">21</xref>] performed a multicenter, phase 2 trial composed of 101 patients, with a median age of 58 (Range: 23&#x02013;76). It was noted that all 101 patients experienced an adverse events grade 3 or higher. Of these, the most common effects were neutropenia, anemia, and thrombocytopenia. 53 patients experienced CRS grade 2 or higher, of which the most common symptoms included pyrexia, hypoxia, and hypotension (9 patients). 1 patient with CRS experienced sudden cardiac arrest. No cardiovascular deaths were reported in this study. 39 patients also were diagnosed with tachycardia.</p><p id="Par21">Shalabi et al. [<xref ref-type="bibr" rid="CR22">22</xref>] performed a retrospective study composed of 52 patients, with a median age of 13 (Range: 4&#x02013;30). 37 patients developed CRS, of which 23 patients developed CRS grade 2 or higher. Of patients who developed CRS, 6 patients also developed cardiac dysfunction. 36 patients also developed tachycardia, and 9 patients developed hypotension&#x02014;requiring vasopressor support. In addition, one patient suffered from cardiac arrest. Between the cardiac event group and no cardiac event group, there was no significant difference in baseline LVEF values (p&#x02009;=&#x02009;0.59). However, of the 13 patients with echocardiographic data, 4 patients experienced both decreased LVEF values and increased troponin levels. Abnormal LVEF values were defined as a greater than 10% absolute decrease in LVEF. Lastly, of the 7 patients with BNP data, 6 patients reported with abnormal BNP levels.</p><p id="Par22">Shouval et al. [<xref ref-type="bibr" rid="CR23">23</xref>] performed a retrospective cohort study with 236 patients, with a median age of 65 (IQR: 16). 23 patients experienced cardiac arrhythmias, of which 17 patients experienced atrial fibrillation. 108 patients developed CRS grade 2 or higher. In terms of echocardiographic findings, 12 patients had echocardiograms taken within 90&#x000a0;days of an arrhythmic event. Of those, 3 patients experienced decreased LVEF, which was defined as a decrease in LVEF of at least 10% from baseline to a value below 53%. In addition, of patients who experienced an arrhythmic event, 2/14 had elevated cardiac troponin levels and 6/14 had elevated BNP levels.</p></sec><sec id="Sec6"><title>Summary findings</title><p id="Par23">We organized summary findings as reports on cardiac events (mostly from ECG), echocardiograms, cardiac blood biomarkers associated with CAR-T cardiotoxicity. We also assessed risk factors and confounding factors associated with CAR-T cardiotoxicity.</p></sec><sec id="Sec7"><title>Cardiac Events</title><p id="Par24">Cardiac event summary findings are shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. Nine studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] were in adult (N&#x02009;=&#x02009;1167) and 4 [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] in pediatric (N&#x02009;=&#x02009;264) patients, with a combined total of 1,431 patients. Patients had predominately DLBCL, PMBCL, ALL, and MCL cancers. All patients were treated in facilities within the US, except for one study center in Israel [<xref ref-type="bibr" rid="CR21">21</xref>]. Most studies were performed between 2016 to 2022 but a few were performed in 2010 (CAR-T was approved by the FDA in 2017 [<xref ref-type="bibr" rid="CR24">24</xref>]). Most follow-up time was less than or about a year post therapy with some reported findings during or soon after CAR-T therapy.
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of cardiac event findings. Age is provided as either mean&#x02009;&#x000b1;&#x02009;SD, median (IQR), or median (range). Follow up time is provided as a median. All average incidences are averaged with total number of patients as denominator</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"><bold>Study</bold></th><th align="left"><bold>Location</bold></th><th align="left"><bold>Study Period</bold></th><th align="left"><bold>Follow Up Time</bold></th><th align="left"><bold>Cancer Type</bold></th><th align="left"><bold>Age</bold></th><th align="left"><bold>Race</bold></th><th align="left"><bold>Male/Total</bold></th><th align="left"><bold>Hypotension</bold><sup><bold>a</bold></sup></th><th align="left"><bold>Tachycardia</bold><sup><bold>a</bold></sup></th><th align="left"><bold>Arrhythmia</bold><sup><bold>a</bold></sup></th><th align="left"><bold>CRS</bold><break/><bold>(grade&#x02009;&#x02265;&#x02009;2)</bold></th><th align="left"><bold>HF</bold></th><th align="left"><bold>A-fib</bold></th><th align="left"><bold>CM</bold></th><th align="left"><bold>Myocarditis</bold></th><th align="left"><bold>Cardiac Arrest</bold></th><th align="left"><bold>CV Death</bold></th></tr></thead><tbody><tr><td align="left">Alvi 2019</td><td align="left">MGH and Moffitt Cancer Center</td><td align="left">1/1/16 &#x02013;11/10/18</td><td align="left">10&#x000a0;months</td><td align="left">DLBCL:83, TFL:36, MM:11, Other:7</td><td align="left">62 (16)</td><td align="left">W:126, B:4, O:7</td><td align="left">93/137</td><td align="left">-</td><td align="left">-</td><td align="left">5</td><td align="left">55</td><td align="left">6</td><td align="left">3</td><td align="left">-</td><td align="left">-</td><td align="left">3</td><td align="left">6</td></tr><tr><td align="left">Brammer 2021</td><td align="left">Ohio State University&#x02019;s Cancer Center</td><td align="left">1/2016 &#x02013;12/2019</td><td align="left">16.5&#x000a0;months</td><td align="left">DLBCL:85, FL:2, MCL:3</td><td align="left">61.0&#x02009;&#x000b1;&#x02009;10.9</td><td align="left">W:85, O:5</td><td align="left">52/90</td><td align="left">79<sup>b</sup></td><td align="left">-</td><td align="left">11</td><td align="left">44</td><td align="left">1</td><td align="left">-</td><td align="left">-</td><td align="left">2</td><td align="left">-</td><td align="left">0</td></tr><tr><td align="left">Ganatra 2020</td><td align="left">Dana Farber Cancer Institutes, Boston and Ann Arbor</td><td align="left">2/2016 &#x02013;04/2019</td><td align="left">5.6&#x000a0;months</td><td align="left">DLBCL:137, FL:35, MCL:4, MBL:2, MZL:2, PMBCL:1, others: 6</td><td align="left">63 (range:19&#x02013;80)</td><td align="left">W:170, O:17</td><td align="left">115/187</td><td align="left">-</td><td align="left">-</td><td align="left">13</td><td align="left">86</td><td align="left">6</td><td align="left">-</td><td align="left">12</td><td align="left">-</td><td align="left">-</td><td align="left">4</td></tr><tr><td align="left">Korell 2024</td><td align="left">University Hospital Heidelberg</td><td align="left">10/1/2018 &#x02013;9/30/2022</td><td align="left">3&#x000a0;months</td><td align="left">DLBCL:74, PMBCL:3, FL:5, CLL:9, MCL:13, ALL:19, MM:14</td><td align="left">60 (16)</td><td align="left">-</td><td align="left">31/137</td><td align="left">25</td><td align="left">-</td><td align="left">-</td><td align="left"><p>5</p><p>(CRS&#x02009;&#x02265;&#x02009;3)</p></td><td align="left">17</td><td align="left">5</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Lefebvre 2020</td><td align="left">Hospital of the U of Pennsylvania</td><td align="left">8/2010 &#x02013;1/2019</td><td align="left">15.2&#x000a0;months</td><td align="left">ALL:36, DLBCL:43, CLL:66</td><td align="left">60 (16)</td><td align="left">-</td><td align="left">107/145</td><td align="left">-</td><td align="left">2</td><td align="left">2</td><td align="left">104</td><td align="left">21</td><td align="left">11</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">2</td></tr><tr><td align="left">Lefebvre 2023</td><td align="left">Hospital of the U of Pennsylvania</td><td align="left">6/2019 &#x02013;2/2022</td><td align="left">16.2&#x000a0;months</td><td align="left">Lymphoma:43, ALL:1</td><td align="left">58&#x02009;&#x000b1;&#x02009;11</td><td align="left">W:40, B:3, O:1</td><td align="left">34/44</td><td align="left">-</td><td align="left">-</td><td align="left">0</td><td align="left">11</td><td align="left">1</td><td align="left">1</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">0</td></tr><tr><td align="left">Lee 2023</td><td align="left">Lee Moffitt Cancer Center</td><td align="left">10/2020 &#x02013;10/2021</td><td align="left">10&#x000a0;days</td><td align="left">DLBCL:54, TFL:8, B-ALL:3, MCL:25</td><td align="left">68 (9.5)</td><td align="left">W:86, B:3, O:1</td><td align="left">55/90</td><td align="left">-</td><td align="left">0</td><td align="left">0</td><td align="left">31</td><td align="left">0</td><td align="left">10</td><td align="left">1</td><td align="left">1</td><td align="left">-</td><td align="left">0</td></tr><tr><td align="left">Neelapu 2017</td><td align="left">22 study centers (21 in US and 1 in Israel)</td><td align="left">11/2015&#x02014;9/2016</td><td align="left">15.4&#x000a0;months</td><td align="left">DLBCL:77, PMBCL:8, TFL:16</td><td align="left">58 (range:23&#x02013;76)</td><td align="left">-</td><td align="left">68/101</td><td align="left">9</td><td align="left">39</td><td align="left">-</td><td align="left">53</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">Shouval 2024</td><td align="left">Memorial Sloan Kettering</td><td align="left">04/2016&#x02013;06/2022</td><td align="left">30&#x000a0;days</td><td align="left">LBCL:215, MCL:14, FL:7</td><td align="left">65 (16)</td><td align="left">W:191, A:17, B:13, O:15</td><td align="left">157/236</td><td align="left">-</td><td align="left">-</td><td align="left">23</td><td align="left">108</td><td align="left"/><td align="left">17</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left"><bold>Adult Counts</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">W:698/784</td><td align="left">712/1167</td><td align="left">113</td><td align="left">41</td><td align="left">54</td><td align="left">497</td><td align="left">52</td><td align="left">47</td><td align="left">13</td><td align="left">3</td><td align="left">4</td><td align="left">12</td></tr><tr><td align="left"><bold>Adult Average Incidence</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">89.0% W</td><td align="left">61.0% male</td><td align="left">34.5%</td><td align="left">12.2%</td><td align="left">5.8%</td><td align="left">42.6%</td><td align="left">6.3%</td><td align="left">5.9%</td><td align="left">4.7%</td><td align="left">1.7%</td><td align="left">1.7%</td><td align="left">1.5%</td></tr><tr><td align="left">Burstein 2018</td><td align="left">Children&#x02019;s Hospital of Philadelphia</td><td align="left">4/2012 &#x02013; 9/2016</td><td align="left">6&#x000a0;months</td><td align="left">B-ALL:90, T-ALL:1, B lymphoblastic lymp:1, PMBCL:1</td><td align="left">10 (range: 2&#x02013;27)</td><td align="left">W:71, B:9, H:9, O:4</td><td align="left">51/98</td><td align="left">24</td><td align="left">-</td><td align="left">-</td><td align="left">24</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td align="left">0</td></tr><tr><td align="left">Fitzgerald 2017</td><td align="left">Children&#x02019;s Hospital of Philadelphia</td><td align="left">4/2012 &#x02013; 9/2014</td><td align="left">up to 28&#x000a0;days</td><td align="left">B-ALL:39</td><td align="left">11 (range: 5&#x02013;22)</td><td align="left">W:32, B:3, A:2, O:2</td><td align="left">20/39</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">34</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Maude 2018</td><td align="left">Children&#x02019;s Hospital of Philadelphia a</td><td align="left">4/8/2015 &#x02013; 4/25/2017</td><td align="left">-</td><td align="left">ALL:75</td><td align="left">11 (range: 3&#x02013;23)</td><td align="left">-</td><td align="left">43/75</td><td align="left">13</td><td align="left">-</td><td align="left">-</td><td align="left"><p>35</p><p>(CRS&#x02009;&#x02265;&#x02009;3)</p></td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td></tr><tr><td align="left">Shalabi 2020</td><td align="left">National Cancer Institute</td><td align="left">7/2012 &#x02013; 5/2016</td><td align="left">-</td><td align="left">ALL:50, NHL:2</td><td align="left">13 (range: 4&#x02013;30)</td><td align="left">-</td><td align="left">41/52</td><td align="left">9</td><td align="left">36</td><td align="left">0</td><td align="left">23</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td align="left">-</td></tr><tr><td align="left"><bold>Ped. Counts</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">W:103/137</td><td align="left">155/264</td><td align="left">46</td><td align="left">36</td><td align="left">0</td><td align="left">116</td><td align="left">-</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">2</td><td align="left">0</td></tr><tr><td align="left"><bold>Ped. Average Incidence</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">75.2% W</td><td align="left">58.7% male</td><td align="left">20.4%</td><td align="left">69.2%</td><td align="left">0.0%</td><td align="left">43.9%</td><td align="left">-</td><td align="left">-</td><td align="left">2.6%</td><td align="left">-</td><td align="left">1.3%</td><td align="left">0.0%</td></tr></tbody></table><table-wrap-foot><p><italic>Hypotension</italic> Hypotension-requiring inotropic/vasopressor support, <italic>HF</italic> Heart failure / Decompensation, <italic>Cardiomyopathy</italic> New or worsening Cardiomyopathy, <italic>A-Fib</italic> Atrial Fibrillation, <italic>CM</italic> Cardiomyopathy <italic>CV</italic> Cardiovascular, <italic>DLBCL</italic> Diffuse Large B Cell Lymphoma, <italic>TFL</italic> Transformed Follicular Lymphoma, <italic>B-ALL</italic> B-cell Acute Lymphoblastic Leukemia, <italic>LBCL</italic> Large B-cell Lymphoma, <italic>MCL</italic> Mantle Cell Lymphoma, <italic>T-ALL</italic> T-cell Acute Lymphoblastic Leukemia, <italic>PMBCL</italic> Primary Mediastinal Large B-Cell Lymphoma, <italic>MM</italic> Multiple Myeloma, <italic>ALL</italic> Acute Lymphoblastic Leukemia, <italic>CLL</italic> Chronic Lymphocytic Leukemia, <italic><underline>NHL</underline></italic> Non-Hodgkin&#x02019;s Lymphoma <italic>TFL</italic> Transformed Follicular Lymphoma, <italic>BL</italic>, Burkitt Lymphoma, FL, Follicular Lymphoma <italic>MDL</italic> Mediastinal B-cell Lymphoma, <italic>MZL</italic> Marginal Zone Lymphoma, <italic>W</italic> White, <italic>B</italic> Black, <italic>A</italic> Asian, <italic>O</italic> Other, <italic>H</italic> Hispanic</p><p><sup>a</sup>hypotension, tachycardia, and arrhythmia may occur in the context of CRS, as it is not always described in the papers</p><p><sup>b</sup>includes both Hypotension-requiring and non-requiring inotropic/vasopressor support and patient</p></table-wrap-foot></table-wrap></p><p id="Par25">Of the adult patients, 60.0% were male and 89.0% were white. Roughly half of all adult patients (42.6%) had CRS grade 2 or higher. The most prevalent cardiotoxic effects were hypotension-requiring inotropic or vasopressor support (34.5%) and tachycardia (12.2%). Note that hypotension and tachycardia are part of the CRS grade definition. The remaining cardiac event findings included heart failure/decompensation (6.3%), atrial fibrillation (5.9%), new or worsening cardiomyopathy (4.7%), arrhythmia (5.8%), myocarditis (1.7%), cardiac arrest (1.7%), and cardiovascular death (1.5%).</p><p id="Par26">Of the pediatric patients, 58.7% were male and 75.2% were white. Pediatric patients had higher incidence of tachycardia (69.2% vs 12.2%) but lower incidence of hypotension (20.4% vs 34.5%) compared to adults. The physiological differences between adult pediatric patients contributed to the differences in tachycardia and hypotension, namely, pediatric patients are more susceptible to tachycardia and less susceptible to hypotension. Pediatric patients showed similar prevalence of CRS grade&#x02009;&#x02265;&#x02009;2 (43.9% vs 42.6%), new or worsening cardiomyopathy (2.6% vs 4.7%), arrhythmia (0.0% vs 5.8%), cardiac arrest (1.3% vs 1.7%), and cardiovascular death (0.0% vs 1.5%). Studies on pediatric patients are sparse, with only 4 studies and 264 patients to date.</p></sec><sec id="Sec8"><title>Echocardiogram</title><p id="Par27">ECG summary findings are shown in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. Seven studies [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR16">16</xref>&#x02013;<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] were in adult (N&#x02009;=&#x02009;976) and 3 [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] in pediatric (N&#x02009;=&#x02009;189) patients, with a combined total of 1,165 patients. Patients had predominately DLBCL, PMBCL, ALL, and MCL cancers. Most follow-up time was less than or about a year post therapy with some reported findings during or soon after CAR-T therapy.
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Summary of echo findings. Age is provided as either mean&#x02009;&#x000b1;&#x02009;SD, median (IQR), or median (range). All average incidences are averaged with total number of patients as denominator. White; B:Black;:Asian; O:Other; H:Hispanic</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left"><bold>Study</bold></th><th align="left"><bold>Location</bold></th><th align="left"><bold>Study Period</bold></th><th align="left"><bold>Follow Up Time</bold></th><th align="left"><bold>Cancer Type</bold></th><th align="left"><bold>Age</bold></th><th align="left"><bold>Male/Total</bold></th><th align="left"><bold>Race</bold></th><th align="left"><bold>CRS (grade&#x02009;&#x02265;&#x02009;2)</bold></th><th align="left"><bold>Abnormal Echo</bold></th><th align="left"><bold>Systolic Dysfunction</bold></th><th align="left"><bold>Diastolic Dysfunction</bold></th></tr></thead><tbody><tr><td align="left"><bold>Adult</bold></td><td align="left">Alvi 2019</td><td align="left">Massachusetts General Hospital and Moffitt Cancer Center</td><td align="left">1/1/16&#x02014;11/10/18</td><td align="left">10&#x000a0;months</td><td align="left">DLBCL:83, TFL:36, MM:11, Other:7</td><td align="left">62 (16)</td><td align="left">93/137</td><td align="left">W:126, B:4, O:7</td><td align="left">55</td><td align="left">-</td><td align="left">8/29<sup>a</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Ganatra 2020</td><td align="left">Dana Farber Cancer Institutes, Boston and Ann Arbor</td><td align="left">2/2016&#x02014;04/2019</td><td align="left">5.6&#x000a0;months</td><td align="left">DLBCL:137, FL:35, MCL:4, MBL:2, MZL:2, PMBCL:1, others: 6</td><td align="left">63 (range:19&#x02013;80)</td><td align="left">115/187</td><td align="left">W:170, O:17</td><td align="left">86</td><td align="left">-</td><td align="left">12/116<sup>a</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Korell 2024</td><td align="left">University Hospital Heidelberg</td><td align="left">10/1/2018&#x02014;9/30/2022</td><td align="left">3&#x000a0;months</td><td align="left">DLBCL:74, PMBCL:3, FL:5, CLL:9, MCL:13, ALL:19, MM:14</td><td align="left">60 (16)</td><td align="left">31/137</td><td align="left">-</td><td align="left">5 (CRS&#x02009;&#x02265;&#x02009;3)</td><td align="left">8/137</td><td align="left">4/137<sup>a</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Lefebvre 2020</td><td align="left">Hospital of the University of Pennsylvania</td><td align="left">8/2010&#x02014;1/2019</td><td align="left">15.2&#x000a0;months</td><td align="left">ALL:36, DLBCL:43, CLL:66</td><td align="left">60 (16)</td><td align="left">107/145</td><td align="left">-</td><td align="left">104</td><td align="left">-</td><td align="left">-</td><td align="left">26/145<sup>b</sup></td></tr><tr><td align="left"/><td align="left">Lefebvre 2023</td><td align="left">Hospital of the University of Pennsylvania</td><td align="left">6/2019&#x02014;2/2022</td><td align="left">16.2&#x000a0;months</td><td align="left">Lymphoma:43, ALL:1</td><td align="left">58&#x02009;&#x000b1;&#x02009;11</td><td align="left">34/44</td><td align="left">W:40, B:3, O:1</td><td align="left">11</td><td align="left">0/44</td><td align="left">0/44<sup>a</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Lee 2023</td><td align="left">Lee Moffitt Cancer Center</td><td align="left">10/2020&#x02014;10/2021</td><td align="left">10&#x000a0;days</td><td align="left">DLBCL:54, TFL:8, B-ALL:3, MCL:25</td><td align="left">68 (9.5)</td><td align="left">55/90</td><td align="left">W:86, B:3, O:1</td><td align="left">31</td><td align="left">1/90</td><td align="left">1/90<sup>a</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Shouval 2024</td><td align="left">Memorial Sloan Kettering</td><td align="left">04/2016&#x02013;06/2022</td><td align="left">30&#x000a0;days</td><td align="left">LBCL:215, MCL:14, FL:7</td><td align="left">65 (16)</td><td align="left">157/236</td><td align="left">W:191, A:17, B:13, O:15</td><td align="left">108</td><td align="left">-</td><td align="left">3/12<sup>e</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left"><bold>Adult Counts:</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">592/976</td><td align="left">W:487/557</td><td align="left">292</td><td align="left">9</td><td align="left">25</td><td align="left">26</td></tr><tr><td align="left"/><td align="left"><bold>Adult Average Incidence:</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">60.7% male</td><td align="left">87.4% W</td><td align="left">47.7%</td><td align="left">2.3%</td><td align="left">9.0%</td><td align="left">17.9%</td></tr><tr><td align="left"/><td align="left">Burstein 2018</td><td align="left">Children&#x02019;s Hospital of Philadelphia</td><td align="left">4/2012&#x02014;9/2016</td><td align="left">6&#x000a0;months</td><td align="left">B-ALL:90, T-ALL:1, B lymphoblastic lymp:1, PMBCL:1</td><td align="left">10 (range: 2&#x02013;27)</td><td align="left">51/98</td><td align="left">W:71, B:9, H:9, O:4</td><td align="left">24</td><td align="left">10/24</td><td align="left">10/24<sup>c</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Fitzgerald 2017</td><td align="left">The Children&#x02019;s Hospital of Philadelphia</td><td align="left">4/2012&#x02014;9/2014</td><td align="left">up to 28&#x000a0;days</td><td align="left">B-ALL:39</td><td align="left">11 (range: 5&#x02013;22)</td><td align="left">20/39</td><td align="left">W:32, B:3, A:2, O:2</td><td align="left">34</td><td align="left">-</td><td align="left">1/39<sup>d</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left">Shalabi 2020</td><td align="left">National Cancer Institute in Bethesda, Maryland</td><td align="left">7/2012&#x02014;5/2016</td><td align="left">-</td><td align="left">ALL:50, NHL:2</td><td align="left">13 (range: 4&#x02013;30)</td><td align="left">41/52</td><td align="left">-</td><td align="left">23</td><td align="left">-</td><td align="left">4/13<sup>a</sup></td><td align="left">-</td></tr><tr><td align="left"/><td align="left"><bold>Pediatric Counts:</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">112/189</td><td align="left">W:103/137</td><td align="left">81</td><td align="left">10</td><td align="left">15</td><td align="left">-</td></tr><tr><td align="left"/><td align="left"><bold>Pediatric Average Incidence:</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">59.2% male</td><td align="left">75.2% W</td><td align="left">42.9%</td><td align="left">41.7%</td><td align="left">19.7%</td><td align="left">-</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>defined as a reduction was defined as a decrease of at least 10 percentage points in left ventricular ejection fraction (LVEF) to a value below 50%</p><p><sup>b</sup>defined as normal (Grade 0) to impaired relaxation (Grade I), to pseudo normal (Grade II), to restrictive (Grade III), and irreversibly restrictive (Grade IV)</p><p><sup>c</sup>based on echocardiographic evidence from study</p><p><sup>d</sup>not experimentally defined in the study</p><p><sup>e</sup>defined as a decrease in left ventricular ejection fraction (LVEF) of at least 10% from baseline to a value below 53%</p></table-wrap-foot></table-wrap></p><p id="Par28">Of the adult patients, 60.7% were male and 87.4% were white. Roughly half of all patients (47.7%) had CRS grade 2 or higher. The most prevalent echocardiographic changes were systolic dysfunction (9.0%) and diastolic dysfunction (17.9%). Other echocardiographic changes were categorized as abnormal echocardiogram findings (2.3%). Definitions for abnormal echocardiogram findings varied among papers.</p><p id="Par29">Of the pediatric patients, 59.2% were male and 75.2% were white. Pediatric patients had higher incidence of abnormal echocardiograms (41.7% vs 2.3%) and systolic dysfunction (19.7% vs 8.4%) compared to adults. No pediatric data was available for diastolic dysfunction. Pediatric patients had slightly lower incidences of CRS grade&#x02009;&#x02265;&#x02009;2 (42.9% vs 47.7%).</p></sec><sec id="Sec9"><title>Blood biomarkers</title><p id="Par30">Biomarker findings are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. There were only 6 [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>] studies (N&#x02009;=&#x02009;657 patients) reporting biomarkers, of which 65.6% were male, and most patients were (85.1%) white. About one-third (38.4%) of all patients had CRS grade&#x02009;&#x02265;&#x02009;2. Greater than half (59.5%) of all patients had abnormal BNP levels, and roughly a quarter (26.4%) of patients had abnormal troponin levels. Definitions for abnormal BNP and troponin levels varied significantly across papers.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Summary of biomarker findings. Age is provided as either mean&#x02009;&#x000b1;&#x02009;SD, median (IQR), or median (range). All average incidences are averaged with total number of patients as denominator. White; B:Black;:Asian; O:Other; H:Hispanic</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Study</th><th align="left">Location</th><th align="left">Study Period</th><th align="left">Follow Up Time</th><th align="left">Cancer Type</th><th align="left">Age</th><th align="left">Race</th><th align="left">Male/Total</th><th align="left">CRS<break/>(grade&#x02009;&#x02265;&#x02009;2)</th><th align="left">Abnormal Troponin</th><th align="left">Abnormal BNP</th></tr></thead><tbody><tr><td align="left">Alvi 2019</td><td align="left">Massachusetts General Hospital and Moffitt Cancer Center</td><td align="left">1/1/16&#x02014;11/10/18</td><td align="left">10&#x000a0;months</td><td align="left">DLBCL:83, TFL:36, MM:11, Other:7</td><td align="left">62 (16)</td><td align="left">W:126, B:4, O:7</td><td align="left">93/137</td><td align="left">55</td><td align="left">29/53</td><td align="left">-</td></tr><tr><td align="left">Burstein 2018</td><td align="left">Children&#x02019;s Hospital of Philadelphia</td><td align="left">4/2012&#x02014;9/2016</td><td align="left">6&#x000a0;months</td><td align="left">B-ALL:90, T-ALL:1, B lymphoblastic lymp:1, PMBCL:1</td><td align="left">10 (range: 2&#x02013;27)</td><td align="left">W:71, B:9, H:9, O:4</td><td align="left">51/98</td><td align="left">24</td><td align="left">-</td><td align="left">12/13</td></tr><tr><td align="left">Lee 2023</td><td align="left">Lee Moffitt Cancer Center</td><td align="left">10/2020&#x02014;10/2021</td><td align="left">10&#x000a0;days</td><td align="left">DLBCL:54, TFL:8, B-ALL:3, MCL:25</td><td align="left">68 (9.5)</td><td align="left">W:86, B:3, O:1</td><td align="left">55/90</td><td align="left">31</td><td align="left">0/88</td><td align="left">11/88</td></tr><tr><td align="left">Lefebvre 2023</td><td align="left">Hospital of the University of Pennsylvania</td><td align="left">6/2019&#x02014;2/2022</td><td align="left">16.2&#x000a0;months</td><td align="left">Lymphoma:43, ALL:1</td><td align="left">58&#x02009;&#x000b1;&#x02009;11</td><td align="left">W:40, B:3, O:1</td><td align="left">34/44</td><td align="left">11</td><td align="left">-</td><td align="left">14/23</td></tr><tr><td align="left">Shalabi 2020</td><td align="left">National Cancer Institute in Bethesda, Maryland</td><td align="left">7/2012&#x02014;5/2016</td><td align="left">-</td><td align="left">ALL:50, NHL:2</td><td align="left">13 (range: 4&#x02013;30)</td><td align="left">-</td><td align="left">41/52</td><td align="left">23</td><td align="left">4/13</td><td align="left">6/7</td></tr><tr><td align="left">Shouval 2024</td><td align="left">Memorial Sloan Kettering</td><td align="left">04/2016&#x02013;06/2022</td><td align="left">30&#x000a0;days</td><td align="left">LBCL:215, MCL:14, FL:7</td><td align="left">65 (16)</td><td align="left">W:191, A:17, B:13, O:15</td><td align="left">157/236</td><td align="left">108</td><td align="left">2/12</td><td align="left">6/14</td></tr><tr><td align="left"><bold>Counts:</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">W:514/605</td><td align="left">431/657</td><td align="left">252</td><td align="left">35</td><td align="left">49</td></tr><tr><td align="left"><bold>Average Incidence:</bold></td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left">85.1% W</td><td align="left">65.6% male</td><td align="left">38.4%</td><td align="left">26.4%</td><td align="left">59.5%</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Risk Factors for Cardiotoxicity</title><p id="Par31">Only four papers statistically modeled risk factors for cardiotoxicity to our knowledge. In the pediatric population, Burstein et al. [<xref ref-type="bibr" rid="CR14">14</xref>] found pretreatment blast percentage&#x02009;&#x0003e;&#x02009;25% on bone marrow biopsy was the most predominant factor associated with increased risk for cardiac events (odds ratio, 15.5; 95% CI, 5.1 to 47.1; P&#x02009;&#x0003c;&#x02009;0.001) (N&#x02009;=&#x02009;98 patients). Patients with lower ejection fraction (p&#x02009;=&#x02009;0.019) or diastolic dysfunction (p&#x02009;=&#x02009;0.021) before treatment had increased rates of hypotension-requiring inotropic support. Notably, pre-existing cardiomyopathy (p&#x02009;=&#x02009;0.062), TBI (p&#x02009;=&#x02009;0.629), or higher anthracycline dose (p&#x02009;=&#x02009;0.444) were not associated with hypotension-requiring inotropic support. In an adult study (n&#x02009;=&#x02009;236), Shouval et al. [<xref ref-type="bibr" rid="CR23">23</xref>] found that risk factors for atrial arrhythmia post CAR-T treatment were a history of atrial arrhythmia (OR&#x02009;=&#x02009;6.80 [2.39&#x02013;19.6]) and using CAR-T product with a CD28-costimulatory domain (OR&#x02009;=&#x02009;5.17 [1.72&#x02013;18.6]) in a multivariable analysis. Lefebvre et al., [<xref ref-type="bibr" rid="CR19">19</xref>] found risk factors associated with a primary endpoint of MACE (defined as cardiovascular death, symptomatic heart failure, acute coronary syndrome, ischemic stroke and de novo cardiac arrhythmia) included prior atrial fibrillation (<italic>p</italic>&#x02009;=&#x02009;0.035), aspirin use (<italic>p</italic>&#x02009;=&#x02009;0.034), statin use (<italic>p</italic>&#x02009;=&#x02009;0.025), insulin use (<italic>p</italic>&#x02009;=&#x02009;0.005), baseline creatinine levels (<italic>p</italic>&#x02009;=&#x02009;0.026), overall CRS grading (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), CRS grade 2 (<italic>p</italic>&#x02009;=&#x02009;0.029), CRS grade 3 (<italic>p</italic>&#x02009;=&#x02009;0.002), CRS grade 4 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001), diastolic blood pressure (<italic>p</italic>&#x02009;=&#x02009;0.007), hemoglobin (p&#x02009;=&#x02009;0.035), platelet count (<italic>p</italic>&#x02009;=&#x02009;0.027), and a higher mitral E/e&#x02019; ratio (<italic>p</italic>&#x02009;=&#x02009;0.046) using univariable Cox proportional cause-specific hazards regression. Multivariable Cox proportional cause-specific hazards regression analysis determined that baseline creatinine and Grade 3 or 4 CRS were independently associated with MACE. Alvi et al. [<xref ref-type="bibr" rid="CR12">12</xref>] found a longer duration from the development of CRS to the administration of tocilizumab to be associated with an increased likelihood of having a positive troponin with a hazard ratio analysis (adjusted p&#x02009;=&#x02009;0.008).</p><p id="Par32">Given the small sample size and the large number of covariates, results from these statistical modeling need to be interpreted with caution.</p></sec><sec id="Sec11"><title>Future Perspectives</title><p id="Par33">With CAR-T therapy FDA approval in 2017 [<xref ref-type="bibr" rid="CR24">24</xref>], it is not surprising that the sample sizes reported in the literature are small. Future studies need to further include larger cohorts, more diverse races and ethnicities to achieve broader generalizability. Future studies should include cardiac computed tomography and magnetic resonance imaging, relevant blood biomarkers, as well as other tests (such as cardiac stress test). Future studies should also include long-term monitoring of cardiac function post CAR-T treatment. The contributions of pre-existing cardiac disease and comorbidities and prior exposure to cardiotoxic therapies to CAR-T cardiotoxicity need further investigation. Statistical modeling is needed to identify risk factors of CAR-T cardiotoxicity. Identifying risk factors could help to refine CAR-T constructs to minimize off-target effects and developing cardioprotective agents for CAR-T therapy.</p></sec><sec id="Sec12"><title>Limitations</title><p id="Par34">We did not perform meta-analysis of these cardiotoxicity data from the literature because of small sample sizes and non-uniform reporting. CAR-T also has other side effects (such as neurotoxicity) that were not reviewed in this study.</p></sec></sec><sec id="Sec13"><title>Conclusions</title><p id="Par35">CAR-T therapy is associated with significant risks for acute and subacute cardiotoxicity. The long-term effects beyond a year post treatment remain largely unknown and long-term follow-up studies are warranted. Improved understanding of the incidence, clinical manifestation, mechanisms, risk factors, and management strategies for CAR-T-induced cardiotoxicity is essential for maximizing therapeutic efficacy while minimizing adverse cardiotoxicity effects.</p></sec><sec id="Sec14"><title>Key References</title><p id="Par36">
<list list-type="bullet"><list-item><p id="Par37">Korell, F.; Entenmann, L.; Romann, S.; Giannitsis, E.; Schmitt, A.; Muller-Tidow, C.; Frey, N.; Dreger, P.; Schmitt, M.; Lehmann, L.H. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. <italic>EClinicalMedicine</italic>
<bold>2024</bold>, <italic>69</italic>, 102504, 10.1016/j.eclinm.2024.102504.<list list-type="bullet"><list-item><p id="Par38">This prospective cohort study aimed to determine the efficacy of cardiac biomarkers in predicting cardiac events following CAR-T therapy in adult patients, as well as assessing potential cardiotoxicities.</p></list-item></list></p></list-item><list-item><p id="Par39">Lefebvre, B.; Kang, Y.; Vakilpour, A.; Onoue, T.; Frey, N.V.; Brahmbhatt, P.; Huang, B.; Oladuja, K.; Koropeckyj-Cox, D.; Wiredu, C.; et al. Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study. <italic>JACC CardioOncol</italic>
<bold>2023</bold>, <italic>5</italic>, 747&#x02013;754, 10.1016/j.jaccao.2023.07.009.<list list-type="bullet"><list-item><p id="Par40">This prospective observational study utilized major adverse cardiovascular events&#x000a0;(MACE) as a primary endpoint to study cardiotoxic effects of CAR-T therapy in adult patients.</p></list-item></list></p></list-item><list-item><p id="Par41">Shouval, R.; Goldman, A.; Flynn, J.R.; El-Moghraby, A.; Rehman, M.; Devlin, S.M.; Corona, M.; Landego, I.; Lin, R.J.; Scordo, M.; et al. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. <italic>Br J Haematol</italic>
<bold>2024</bold>, 10.1111/bjh.19497.<list list-type="bullet"><list-item><p id="Par42">This study analyzes the incidence and risk factors of developing atrial arrhythmias after CAR-T therapy. Inflammatory markers and biomarkers were also analyzed in the post CAR-T therapy setting.</p></list-item></list></p></list-item></list></p></sec><sec id="Sec15" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11912_2024_1634_MOESM1_ESM.docx"><caption><p>Supplementary file1 (DOCX 14 KB)</p></caption></media></supplementary-material></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>No financial contributions or competing interests are relevant to disclose in this study.</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>T.J. and J.S. performed literature search, conceptualized the study, designed study, analyzed data, wrote manuscript A.A., R.S., L.Z.: reviewed analysis, participated in discussion, and edited manuscript T.D. conceptualized the study, supervised the study, wrote/edit manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>No funding was acquired for this study.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par43">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>JF</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name></person-group><article-title>Engineering CAR-T cells</article-title><source>Biomark Res</source><year>2017</year><volume>5</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/s40364-017-0102-y</pub-id><pub-id pub-id-type="pmid">28652918</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Zhang C, Liu J, Zhong JF, Zhang X. Engineering CAR-T cells. Biomark Res. 2017;5:22. 10.1186/s40364-017-0102-y.<pub-id pub-id-type="pmid">28652918</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Mitra</surname><given-names>A</given-names></name><name><surname>Barua</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Ganguly</surname><given-names>S</given-names></name><name><surname>Feng</surname><given-names>Q</given-names></name><name><surname>He</surname><given-names>B</given-names></name></person-group><article-title>From bench to bedside: the history and progress of CAR T cell therapy</article-title><source>Front Immunol</source><year>2023</year><volume>14</volume><fpage>1188049</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2023.1188049</pub-id><pub-id pub-id-type="pmid">37256141</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. 10.3389/fimmu.2023.1188049.<pub-id pub-id-type="pmid">37256141</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Maude</surname><given-names>SL</given-names></name><name><surname>Laetsch</surname><given-names>TW</given-names></name><name><surname>Buechner</surname><given-names>J</given-names></name><name><surname>Rives</surname><given-names>S</given-names></name><name><surname>Boyer</surname><given-names>M</given-names></name><name><surname>Bittencourt</surname><given-names>H</given-names></name><name><surname>Bader</surname><given-names>P</given-names></name><name><surname>Verneris</surname><given-names>MR</given-names></name><name><surname>Stefanski</surname><given-names>HE</given-names></name><name><surname>Myers</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia</article-title><source>N Engl J Med</source><year>2018</year><volume>378</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709866</pub-id><pub-id pub-id-type="pmid">29385370</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018;378:439&#x02013;48. 10.1056/NEJMoa1709866.<pub-id pub-id-type="pmid">29385370</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>AK</given-names></name><name><surname>Chen</surname><given-names>DH</given-names></name><name><surname>Guha</surname><given-names>A</given-names></name><name><surname>Mackenzie</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>JM</given-names></name><name><surname>Roddie</surname><given-names>C</given-names></name></person-group><article-title>CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity?</article-title><source>JACC CardioOncol</source><year>2020</year><volume>2</volume><fpage>97</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2020.02.011</pub-id><pub-id pub-id-type="pmid">34396213</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Ghosh AK, Chen DH, Guha A, Mackenzie S, Walker JM, Roddie C. CAR T Cell Therapy-Related Cardiovascular Outcomes and Management: Systemic Disease or Direct Cardiotoxicity? JACC CardioOncol. 2020;2:97&#x02013;109. 10.1016/j.jaccao.2020.02.011.<pub-id pub-id-type="pmid">34396213</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Chacko S, Haseeb S, Glover BM, Wallbridge D, Harper A (2018)The role of biomarkers in the diagnosis and risk stratification of acute coronary syndrome. Future science OA. 4(1):FSO251.10.4155/fsoa-2017-0036.</mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Camilli</surname><given-names>M</given-names></name><name><surname>Maggio</surname><given-names>L</given-names></name><name><surname>Tinti</surname><given-names>L</given-names></name><name><surname>Lamendola</surname><given-names>P</given-names></name><name><surname>Lanza</surname><given-names>GA</given-names></name><name><surname>Crea</surname><given-names>F</given-names></name><name><surname>Lombardo</surname><given-names>A</given-names></name></person-group><article-title>Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal</article-title><source>Front Cardiovasc Med</source><year>2023</year><volume>10</volume><fpage>1090103</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2023.1090103</pub-id><pub-id pub-id-type="pmid">36895831</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Camilli M, Maggio L, Tinti L, Lamendola P, Lanza GA, Crea F, Lombardo A. Chimeric antigen receptor-T cell therapy-related cardiotoxicity in adults and children cancer patients: A clinical appraisal. Front Cardiovasc Med. 2023;10:1090103. 10.3389/fcvm.2023.1090103.<pub-id pub-id-type="pmid">36895831</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name></person-group><article-title>Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies</article-title><source>J Exp Clin Cancer Res</source><year>2021</year><volume>40</volume><fpage>367</fpage><pub-id pub-id-type="doi">10.1186/s13046-021-02148-6</pub-id><pub-id pub-id-type="pmid">34794490</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Xiao X, Huang S, Chen S, Wang Y, Sun Q, Xu X, Li Y. Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. J Exp Clin Cancer Res. 2021;40:367. 10.1186/s13046-021-02148-6.<pub-id pub-id-type="pmid">34794490</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DW</given-names></name><name><surname>Santomasso</surname><given-names>BD</given-names></name><name><surname>Locke</surname><given-names>FL</given-names></name><name><surname>Ghobadi</surname><given-names>A</given-names></name><name><surname>Turtle</surname><given-names>CJ</given-names></name><name><surname>Brudno</surname><given-names>JN</given-names></name><name><surname>Maus</surname><given-names>MV</given-names></name><name><surname>Park</surname><given-names>JH</given-names></name><name><surname>Mead</surname><given-names>E</given-names></name><name><surname>Pavletic</surname><given-names>S</given-names></name><etal/></person-group><article-title>ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells</article-title><source>Biol Blood Marrow Transplant</source><year>2019</year><volume>25</volume><fpage>625</fpage><lpage>638</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2018.12.758</pub-id><pub-id pub-id-type="pmid">30592986</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25:625&#x02013;38. 10.1016/j.bbmt.2018.12.758.<pub-id pub-id-type="pmid">30592986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>A</given-names></name><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Eljalby</surname><given-names>M</given-names></name><name><surname>Ramakrishnan</surname><given-names>P</given-names></name><name><surname>Anderson</surname><given-names>LD</given-names><suffix>Jr</suffix></name><name><surname>Awan</surname><given-names>FT</given-names></name><name><surname>Chandra</surname><given-names>A</given-names></name><name><surname>Vallabhaneni</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Zaha</surname><given-names>VG</given-names></name></person-group><article-title>Cardiovascular disease and chimeric antigen receptor cellular therapy</article-title><source>Front Cardiovasc Med</source><year>2022</year><volume>9</volume><fpage>932347</fpage><pub-id pub-id-type="doi">10.3389/fcvm.2022.932347</pub-id><pub-id pub-id-type="pmid">36211558</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Rao A, Stewart A, Eljalby M, Ramakrishnan P, Anderson LD Jr, Awan FT, Chandra A, Vallabhaneni S, Zhang K, Zaha VG. Cardiovascular disease and chimeric antigen receptor cellular therapy. Front Cardiovasc Med. 2022;9:932347. 10.3389/fcvm.2022.932347.<pub-id pub-id-type="pmid">36211558</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S</given-names></name><name><surname>Hao</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name></person-group><article-title>Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies</article-title><source>J Immunol Res</source><year>2018</year><volume>2018</volume><fpage>2386187</fpage><pub-id pub-id-type="doi">10.1155/2018/2386187</pub-id><pub-id pub-id-type="pmid">29850622</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Sun S, Hao H, Yang G, Zhang Y, Fu Y. Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies. J Immunol Res. 2018;2018:2386187. 10.1155/2018/2386187.<pub-id pub-id-type="pmid">29850622</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Aldoss</surname><given-names>I</given-names></name><name><surname>Khaled</surname><given-names>SK</given-names></name><name><surname>Budde</surname><given-names>E</given-names></name><name><surname>Stein</surname><given-names>AS</given-names></name></person-group><article-title>Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment</article-title><source>Curr Oncol Rep</source><year>2019</year><volume>21</volume><fpage>4</fpage><pub-id pub-id-type="doi">10.1007/s11912-019-0753-y</pub-id><pub-id pub-id-type="pmid">30666425</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Aldoss I, Khaled SK, Budde E, Stein AS. Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment. Curr Oncol Rep. 2019;21:4. 10.1007/s11912-019-0753-y.<pub-id pub-id-type="pmid">30666425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Alvi</surname><given-names>RM</given-names></name><name><surname>Frigault</surname><given-names>MJ</given-names></name><name><surname>Fradley</surname><given-names>MG</given-names></name><name><surname>Jain</surname><given-names>MD</given-names></name><name><surname>Mahmood</surname><given-names>SS</given-names></name><name><surname>Awadalla</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Zlotoff</surname><given-names>DA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Drobni</surname><given-names>ZD</given-names></name><etal/></person-group><article-title>Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)</article-title><source>J Am Coll Cardiol</source><year>2019</year><volume>74</volume><fpage>3099</fpage><lpage>3108</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2019.10.038</pub-id><pub-id pub-id-type="pmid">31856966</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, Lee DH, Zlotoff DA, Zhang L, Drobni ZD, et al. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). J Am Coll Cardiol. 2019;74:3099&#x02013;108. 10.1016/j.jacc.2019.10.038.<pub-id pub-id-type="pmid">31856966</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. J ImmunoTher Cancer. 2021;9(8).10.1136/jitc-2020-002303.</mixed-citation></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Burstein</surname><given-names>DS</given-names></name><name><surname>Maude</surname><given-names>S</given-names></name><name><surname>Grupp</surname><given-names>S</given-names></name><name><surname>Griffis</surname><given-names>H</given-names></name><name><surname>Rossano</surname><given-names>J</given-names></name><name><surname>Lin</surname><given-names>K</given-names></name></person-group><article-title>Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience</article-title><source>Biol Blood Marrow Transplant</source><year>2018</year><volume>24</volume><fpage>1590</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1016/j.bbmt.2018.05.014</pub-id><pub-id pub-id-type="pmid">29772353</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Burstein DS, Maude S, Grupp S, Griffis H, Rossano J, Lin K. Cardiac Profile of Chimeric Antigen Receptor T Cell Therapy in Children: A Single-Institution Experience. Biol Blood Marrow Transplant. 2018;24:1590&#x02013;5. 10.1016/j.bbmt.2018.05.014.<pub-id pub-id-type="pmid">29772353</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Fitzgerald</surname><given-names>JC</given-names></name><name><surname>Weiss</surname><given-names>SL</given-names></name><name><surname>Maude</surname><given-names>SL</given-names></name><name><surname>Barrett</surname><given-names>DM</given-names></name><name><surname>Lacey</surname><given-names>SF</given-names></name><name><surname>Melenhorst</surname><given-names>JJ</given-names></name><name><surname>Shaw</surname><given-names>P</given-names></name><name><surname>Berg</surname><given-names>RA</given-names></name><name><surname>June</surname><given-names>CH</given-names></name><name><surname>Porter</surname><given-names>DL</given-names></name><etal/></person-group><article-title>Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia</article-title><source>Crit Care Med</source><year>2017</year><volume>45</volume><fpage>e124</fpage><lpage>e131</lpage><pub-id pub-id-type="doi">10.1097/CCM.0000000000002053</pub-id><pub-id pub-id-type="pmid">27632680</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, et al. Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia. Crit Care Med. 2017;45:e124&#x02013;31. 10.1097/CCM.0000000000002053.<pub-id pub-id-type="pmid">27632680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Ganatra</surname><given-names>S</given-names></name><name><surname>Redd</surname><given-names>R</given-names></name><name><surname>Hayek</surname><given-names>SS</given-names></name><name><surname>Parikh</surname><given-names>R</given-names></name><name><surname>Azam</surname><given-names>T</given-names></name><name><surname>Yanik</surname><given-names>GA</given-names></name><name><surname>Spendley</surname><given-names>L</given-names></name><name><surname>Nikiforow</surname><given-names>S</given-names></name><name><surname>Jacobson</surname><given-names>C</given-names></name><name><surname>Nohria</surname><given-names>A</given-names></name></person-group><article-title>Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma</article-title><source>Circulation</source><year>2020</year><volume>142</volume><fpage>1687</fpage><lpage>1690</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.048100</pub-id><pub-id pub-id-type="pmid">33104402</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Ganatra S, Redd R, Hayek SS, Parikh R, Azam T, Yanik GA, Spendley L, Nikiforow S, Jacobson C, Nohria A. Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. Circulation. 2020;142:1687&#x02013;90. 10.1161/CIRCULATIONAHA.120.048100.<pub-id pub-id-type="pmid">33104402</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Korell</surname><given-names>F</given-names></name><name><surname>Entenmann</surname><given-names>L</given-names></name><name><surname>Romann</surname><given-names>S</given-names></name><name><surname>Giannitsis</surname><given-names>E</given-names></name><name><surname>Schmitt</surname><given-names>A</given-names></name><name><surname>Muller-Tidow</surname><given-names>C</given-names></name><name><surname>Frey</surname><given-names>N</given-names></name><name><surname>Dreger</surname><given-names>P</given-names></name><name><surname>Schmitt</surname><given-names>M</given-names></name><name><surname>Lehmann</surname><given-names>LH</given-names></name></person-group><article-title>Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study</article-title><source>EClinicalMedicine</source><year>2024</year><volume>69</volume><fpage>102504</fpage><pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102504</pub-id><pub-id pub-id-type="pmid">38544797</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Korell F, Entenmann L, Romann S, Giannitsis E, Schmitt A, Muller-Tidow C, Frey N, Dreger P, Schmitt M, Lehmann LH. Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study. EClinicalMedicine. 2024;69:102504. 10.1016/j.eclinm.2024.102504.<pub-id pub-id-type="pmid">38544797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>DH</given-names></name><name><surname>Chandrasekhar</surname><given-names>S</given-names></name><name><surname>Jain</surname><given-names>MD</given-names></name><name><surname>Mhaskar</surname><given-names>R</given-names></name><name><surname>Reid</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SB</given-names></name><name><surname>Corallo</surname><given-names>S</given-names></name><name><surname>Hidalgo-Vargas</surname><given-names>MJ</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Chavez</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study</article-title><source>Cardiooncology</source><year>2023</year><volume>9</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.1186/s40959-023-00170-5</pub-id><pub-id pub-id-type="pmid">37005652</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, et al. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023;9:18. 10.1186/s40959-023-00170-5.<pub-id pub-id-type="pmid">37005652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>B</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Frey</surname><given-names>NV</given-names></name><name><surname>Carver</surname><given-names>JR</given-names></name><name><surname>Scherrer-Crosbie</surname><given-names>M</given-names></name></person-group><article-title>Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study</article-title><source>JACC CardioOncol</source><year>2020</year><volume>2</volume><fpage>193</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2020.04.012</pub-id><pub-id pub-id-type="pmid">32776016</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lefebvre B, Kang Y, Smith AM, Frey NV, Carver JR, Scherrer-Crosbie M. Cardiovascular Effects of CAR T Cell Therapy: A Retrospective Study. JACC CardioOncol. 2020;2:193&#x02013;203. 10.1016/j.jaccao.2020.04.012.<pub-id pub-id-type="pmid">32776016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Lefebvre</surname><given-names>B</given-names></name><name><surname>Kang</surname><given-names>Y</given-names></name><name><surname>Vakilpour</surname><given-names>A</given-names></name><name><surname>Onoue</surname><given-names>T</given-names></name><name><surname>Frey</surname><given-names>NV</given-names></name><name><surname>Brahmbhatt</surname><given-names>P</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Oladuja</surname><given-names>K</given-names></name><name><surname>Koropeckyj-Cox</surname><given-names>D</given-names></name><name><surname>Wiredu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study</article-title><source>JACC CardioOncol</source><year>2023</year><volume>5</volume><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="doi">10.1016/j.jaccao.2023.07.009</pub-id><pub-id pub-id-type="pmid">38204993</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Lefebvre B, Kang Y, Vakilpour A, Onoue T, Frey NV, Brahmbhatt P, Huang B, Oladuja K, Koropeckyj-Cox D, Wiredu C, et al. Incidence of MACE in Patients Treated With CAR-T Cell Therapy: A Prospective Study. JACC CardioOncol. 2023;5:747&#x02013;54. 10.1016/j.jaccao.2023.07.009.<pub-id pub-id-type="pmid">38204993</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Neelapu</surname><given-names>SS</given-names></name><name><surname>Locke</surname><given-names>FL</given-names></name><name><surname>Bartlett</surname><given-names>NL</given-names></name><name><surname>Lekakis</surname><given-names>LJ</given-names></name><name><surname>Miklos</surname><given-names>DB</given-names></name><name><surname>Jacobson</surname><given-names>CA</given-names></name><name><surname>Braunschweig</surname><given-names>I</given-names></name><name><surname>Oluwole</surname><given-names>OO</given-names></name><name><surname>Siddiqi</surname><given-names>T</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma</article-title><source>N Engl J Med</source><year>2017</year><volume>377</volume><fpage>2531</fpage><lpage>2544</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707447</pub-id><pub-id pub-id-type="pmid">29226797</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med. 2017;377:2531&#x02013;44. 10.1056/NEJMoa1707447.<pub-id pub-id-type="pmid">29226797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Shalabi H, Sachdev V, Kulshreshtha A, Cohen JW, Yates B, Rosing DR, Sidenko S, Delbrook C, Mackall C, Wiley B, et al. Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies. J Immunother Cancer 2020, 8, 10.1136/jitc-2020-001159</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Shouval</surname><given-names>R</given-names></name><name><surname>Goldman</surname><given-names>A</given-names></name><name><surname>Flynn</surname><given-names>JR</given-names></name><name><surname>El-Moghraby</surname><given-names>A</given-names></name><name><surname>Rehman</surname><given-names>M</given-names></name><name><surname>Devlin</surname><given-names>SM</given-names></name><name><surname>Corona</surname><given-names>M</given-names></name><name><surname>Landego</surname><given-names>I</given-names></name><name><surname>Lin</surname><given-names>RJ</given-names></name><name><surname>Scordo</surname><given-names>M</given-names></name><etal/></person-group><article-title>Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile</article-title><source>Br J Haematol</source><year>2024</year><pub-id pub-id-type="doi">10.1111/bjh.19497</pub-id><pub-id pub-id-type="pmid">38735683</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Shouval R, Goldman A, Flynn JR, El-Moghraby A, Rehman M, Devlin SM, Corona M, Landego I, Lin RJ, Scordo M, et al. Atrial arrhythmias following CAR-chimeric antigen receptor T-cell therapy: Incidence, risk factors and biomarker profile. Br J Haematol. 2024. 10.1111/bjh.19497.<pub-id pub-id-type="pmid">38735683</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Abila</surname><given-names>B</given-names></name><name><surname>Mostafa Kamel</surname><given-names>Y</given-names></name></person-group><article-title>(2023) CAR-T: What Is Next?</article-title><source>Cancers (Basel)</source><year>2023</year><volume>15</volume><issue>3</issue><fpage>663</fpage><pub-id pub-id-type="doi">10.3390/cancers15030663</pub-id><pub-id pub-id-type="pmid">36765623</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Chen YJ, Abila B, Mostafa Kamel Y. (2023) CAR-T: What Is Next? Cancers (Basel). 2023;15(3):663. 10.3390/cancers15030663.<pub-id pub-id-type="pmid">36765623</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>